What is Examorelin?
Examorelin — you may also see it called hexarelin — is a small, synthetic peptide built specifically to trigger the release of growth hormone (GH). It belongs to a family of compounds called growth hormone secretagogues (GHSs). Think of secretagogues as chemical keys: they fit into a specific lock in the body and prompt GH to be released on demand.
Examorelin is closely related to ghrelin, the so-called "hunger hormone" your stomach naturally produces. Like ghrelin, examorelin binds to the growth hormone secretagogue receptor (GHSR) found in the brain. But researchers note that examorelin is chemically more stable and functionally more potent than ghrelin itself.[2] It has attracted scientific interest not just for GH release, but also for possible effects on the heart, kidneys, and other tissues.[2]
It is worth noting that examorelin is also a metabolite of a related compound called alexamorelin — laboratory studies show that human liver enzymes (specifically carboxypeptidase) can convert alexamorelin into examorelin.[6] This relationship is important for researchers studying how the body processes these peptides.
Important: Examorelin is a research compound only. It is not approved for human use. Nothing here is medical advice.
How Examorelin Works
Here is a simple way to picture it. Your pituitary gland — a pea-sized gland at the base of your brain — is like a factory that makes growth hormone. Normally, a signal molecule called GHRH (growth hormone-releasing hormone) acts as the "start button" for that factory. Examorelin mimics that signal by binding to the GHSR receptor, essentially pressing the start button and telling the pituitary to release a pulse of GH.[2]
What makes examorelin interesting beyond GH release is that GHSR receptors are not only in the brain. They are also found in the heart and blood vessels.[2] On top of that, examorelin can bind to a completely different receptor called CD36, which sits on heart tissue and appears to mediate protective effects on the heart independently of GH.[2] So examorelin may be doing several jobs at once — stimulating GH from the brain while also acting directly on tissues in the periphery.
Because GH release triggered by secretagogues like examorelin still follows the body's natural feedback loops, it is less likely to cause runaway, supra-normal GH levels compared with injecting GH directly.[5]
What the Research Shows
Growth Hormone Release and Desensitization
A six-week preclinical study in young beagle dogs found something nuanced about prolonged examorelin use. GH responses initially increased — peaking around week three — then declined by week six. The pituitary appeared to become temporarily less responsive to examorelin (a process called desensitization), though it largely preserved its response to the natural signal GHRH.[3] Interestingly, the appetite-stimulating (orexigenic) effect of examorelin followed a different timeline, suggesting there may be distinct receptor subtypes for the neuroendocrine versus the feeding-related effects.[3] See the dosage chart on this page for the specific protocol used.
Kidney Protection
A 2023 preclinical study looked at examorelin in a rat model of ischemia/reperfusion injury (IRI) — the kind of sudden oxygen-loss damage that can lead to acute kidney injury (AKI). Rats pretreated with examorelin showed less kidney damage: less tubular necrosis, better kidney function markers (lower serum creatinine), and less cell death (apoptosis).[4] The researchers found examorelin appeared to work through a molecular pathway involving proteins called MDM2 and p53 — key regulators of whether a cell lives or dies.[4] Examorelin boosted MDM2 activity while dialing down a harmful form of p53, ultimately reducing apoptosis in kidney cells.[4] The preclinical dose used in this study is listed in the dosage chart below.
Cardiovascular Effects
Research reviews highlight that examorelin's ability to bind both GHSR and the CD36 receptor positions it as a compound with direct cardiovascular actions — beyond just triggering GH release.[2] The CD36 pathway in particular appears linked to cardioprotective signaling, making examorelin a subject of ongoing interest for heart-related research.[2]
Ageing and Longevity Research
Examorelin has been flagged in ageing-science literature as one of the more promising leads for understanding the GH/IGF-1 axis — a hormonal pathway that shifts significantly as we get older — alongside approaches like caloric restriction.[1] Research in this area remains exploratory.
General GHS Research Context
Across the broader class of growth hormone secretagogues, studies suggest these compounds may support lean mass, appetite stimulation, and sleep quality, while generally being well tolerated in short-term studies. However, researchers flag that long-term safety data — including effects on blood sugar (insulin sensitivity) and cancer risk — are still needed.[5]
What Examorelin Is Being Studied For
- Stimulating pulsatile growth hormone release[2]
- Cardiovascular protection and heart function[2]
- Kidney protection against ischemia/reperfusion injury[4]
- GH axis dynamics and desensitization patterns[3]
- Ageing and longevity mechanisms[1]
- Appetite regulation (orexigenic effects)[3]
How Examorelin Is Dosed in Research
Dosing in preclinical studies varies depending on the research question. The dosage chart on this page outlines the two main protocols found in the literature — one for kidney protection in an acute injury model and one for GH secretion and desensitization studies. For weight-based calculations, use the calculator on this page, which can help convert the published preclinical doses for research reference purposes. All dosing information here reflects animal study protocols only and is provided for educational context.
Mixing and Storing Examorelin
Like most research peptides, examorelin typically comes as a lyophilized powder — freeze-dried to extend shelf life. To prepare it for use in research, the powder is reconstituted with bacteriostatic water (sterile water containing a small amount of benzyl alcohol, which slows bacterial growth). Add the water slowly down the side of the vial — never shake it, as that can break down the peptide structure. Gently swirl or roll the vial until the powder fully dissolves. Once reconstituted, store the vial in the refrigerator (2–8 °C) and protect it from light. Unused lyophilized powder should be kept frozen until needed. Always follow the storage guidelines provided by the supplier and handle all research compounds under appropriate laboratory conditions.
Sources
- We are ageing. — BioMed research international, 2014. PMID 25045704.
- The cardiovascular action of hexarelin. — Journal of geriatric cardiology : JGC, 2014. PMID 25278975.
- Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin. — European journal of endocrinology, 1999. PMID 10474131.
- Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. — European journal of medical research, 2023. PMID 37710348.
- The Safety and Efficacy of Growth Hormone Secretagogues. — Sexual medicine reviews, 2018. PMID 28400207.
- Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry. — Journal of analytical toxicology, 2025. PMID 40465419.
EN
BR
ES
FR